Global Hepatic Encephalopathy Treatment Market Size, Trends, and Growth Opportunity, By Drug Class (Antibiotics, Laxatives, L-ornithine, and L-aspartate), By Diagnosis (Blood Tests, CT Scan, and Liver Functioning Tests), By Route of Administration (Oral, Injectable, Intravenous, and Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), By Regional and Forecast to 2030  
Global Hepatic Encephalopathy Treatment Market 
The Global Hepatic Encephalopathy Treatment Market was valued at USD 1,563 million in 2022 and is expected to reach USD 2573.34 million by 2030, at a CAGR 6.43 % during the forecast period 2023- 2030.
Some people with liver illness also develop hepatic encephalopathy (HE), a brain ailment. HE causes a wide range of neuropsychiatric symptoms, from mild cognitive impairment to coma, and it significantly raises the risk of morbidity in people with liver disease. It is seen in cases of cirrhosis, trans-jugular intrahepatic portosystemic shunt surgery, and acute liver failure, which are all categorized as Type A, B, and C HE, respectively.
Hepatic encephalopathy can also be accompanied by more serious symptoms, such as decreased alertness, a shorter attention span, sleep disturbances, mild disorientation, a slower capacity to do mental tasks, and changes in mood or personality. Treatment for individuals experiencing acute episodes of hepatic encephalopathy, prevention of recurrence, and identification and management of factors that may lead to the development of HE is all part of managing OHE. Non-absorbable disaccharides (such as lactitol and lactulose) and non-absorbable antibiotics are the two main medical treatments for HE. 
Market Drivers
Cirrhosis and non-alcoholic fatty liver disease are becoming more common liver illnesses (NAFLD) which is projected to propel the market growth in the coming years. Furthermore, the creation of novel and cutting-edge HE treatments is one of the major factors boosting the Hepatic Encephalopathy Treatment Market. Rifaximin, lactulose, and neomycin are a few new drugs that have recently been authorized for the treatment of HE. These drugs lessen the number of toxins in the gut or stop them from entering the bloodstream, which can lessen the severity of HE symptoms.
Market Restraints
The shortage of qualified medical personnel and the unfavorable reimbursement environment in developing and underdeveloped nations will be important obstacles to the market's expansion. High expenditures related to the treatment as well as research and development would further slow the market's growth rate.
Market Segmentation
Global Hepatic Encephalopathy Treatment Market is segmented into Drug Class, Diagnosis, Route of Administration, and Distribution Channel
Based on Drug Class market is segmented into Antibiotics, Laxatives, L-ornithine, and L-aspartate.
Based Diagnosis market is divided into Blood Tests, CT Scan, and Liver Functioning Tests, 
Based on the Route of Administration market is segmented into Oral, Injectable, Intravenous, and Others.
Based on the Distribution Channel market is segmented into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy
Regional Analysis
Global Hepatic Encephalopathy Treatment Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The earliest adoption of cutting-edge technology, the rising prevalence of liver illnesses in the region, and expanding capacity for research and development are all reasons why North America dominates the market for hepatic encephalopathy treatments. Throughout the forecast period, Asia-Pacific is expected to have significant growth and achieve the highest CAGR. This is a result of increased healthcare infrastructure development costs, an increase in neurological problem instances, and a rise in the amount of research and development being done to treat and manage liver diseases.
Key Players
Various key players are discussed in the Global Hepatic Encephalopathy Treatment Market Report including Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.
Market Taxonomy
By Drug Class
Antibiotics
Laxatives
L-ornithine
L-aspartate

By Diagnosis
Blood Tests
CT Scan
Liver Functioning Tests

By Route of Administration
Oral
Injectable
Intravenous
Others

By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

By Region
·       North America
·       Latin America
·       Europe
·       Asia Pacific
·       Middle East & Africa
 
 

Global Hepatic Encephalopathy Treatment Market 
1 Introduction 
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Hepatic Encephalopathy Treatment Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn 
4.2.6 Post covid-19 world Supply & Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Hepatic Encephalopathy Treatment Market, By Drug Class 
5.1 Y-o-Y Growth Comparison, By Drug Class  
5.2 Global Hepatic Encephalopathy Treatment Market Share Analysis, By Drug Class  
5.3 Global Hepatic Encephalopathy Treatment Market Size and Forecast, By Drug Class 
5.3.1. Antibiotics
5.3.2. Laxatives
5.3.3. L-ornithine
5.3.4. L-aspartate
6 Global Hepatic Encephalopathy Treatment Market, By Diagnosis
6.1 Y-o-Y Growth Comparison, By Diagnosis
6.2 Global Hepatic Encephalopathy Treatment Market Share Analysis, By Diagnosis
6.3 Global Hepatic Encephalopathy Treatment Market Size and Forecast, By Diagnosis
6.3.1 Blood Tests
6.3.2. CT Scan
6.3.3. Liver Functioning Tests
8 Global Hepatic Encephalopathy Treatment Market, By Route of Administration
8.1 Y-o-Y Growth Comparison, By Route of Administration
8.2 Global Hepatic Encephalopathy Treatment Market Share Analysis, By Route of Administration
8.3 Global Hepatic Encephalopathy Treatment Market Size and Forecast, By Route of Administration
8.3.1. Oral
8.3.2. Injectable
8.3.3. Intravenous
8.3.4. Others
9 Global Hepatic Encephalopathy Treatment Market, By Distribution Channel
9.1 Y-o-Y Growth Comparison, By Distribution Channel
9.2 Global Hepatic Encephalopathy Treatment Market Share Analysis, By Distribution Channel
9.3 Global Hepatic Encephalopathy Treatment Market Size and Forecast, By Distribution Channel
9.3.1. Hospital Pharmacy
9.3.2. Online Pharmacy
9.3.3. Retail Pharmacy
10 Global Hepatic Encephalopathy Treatment Market, By Region
10.1. Global Hepatic Encephalopathy Treatment Market Share Analysis, By Region
10.2 .Global Hepatic Encephalopathy Treatment Market Size and Forecast, By Region
11 North America Hepatic Encephalopathy Treatment Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Hepatic Encephalopathy Treatment Market Share Analysis, By Drug Class  
11.3 North America Hepatic Encephalopathy Treatment Market Size and Forecast, By Diagnosis
11.4 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Route of Administration
11.5 North America Hepatic Encephalopathy Treatment Market Size and Forecast, By Distribution Channel
11.6 North America Hepatic Encephalopathy Treatment Market Size and Forecast, By Country
11.6.1 U.S.
11.6.2.Canada
11.6.3. Mexico
12 Europe Hepatic Encephalopathy Treatment Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Hepatic Encephalopathy Treatment Market Share Analysis, By Drug Class  
12.3 Europe Hepatic Encephalopathy Treatment Market Size and Forecast, By Diagnosis
12.4 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Route of Administration
12.5 Europe Hepatic Encephalopathy Treatment Market Size and Forecast, By Distribution Channel
12.6 Europe Hepatic Encephalopathy Treatment Market Size and Forecast, By Country
12.6.1 Germany
12.7.2 France
12.7.3 UK
12.7.4. Rest of Europe
13 Asia Pacific Hepatic Encephalopathy Treatment Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Hepatic Encephalopathy Treatment Market Share Analysis, By Drug Class  
13.3 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Diagnosis
13.4 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Route of Administration
13.5 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Distribution Channel
13.6 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Country
13.6.1 China 
13.6.2 Japan
13.6.3 India
13.6.4. Rest of Asia Pacific
14 6atin America Hepatic Encephalopathy Treatment Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Hepatic Encephalopathy Treatment Market Share Analysis, By Drug Class  
14.3 Latin America Hepatic Encephalopathy Treatment Market Size and Forecast, By Diagnosis
14.4 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Route of Administration
14.5 Latin America Hepatic Encephalopathy Treatment Market Size and Forecast, By Distribution Channel
14.6 Latin America Hepatic Encephalopathy Treatment Market Size and Forecast, Country
14.6.1. Brazil
14.6.2. Rest of Latin America
15 Middle East Hepatic Encephalopathy Treatment Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Hepatic Encephalopathy Treatment Market Share Analysis, By Drug Class  
15.3 Middle East Hepatic Encephalopathy Treatment Market Size and Forecast, By Diagnosis
15.4 Asia Pacific Hepatic Encephalopathy Treatment Market Size and Forecast, By Route of Administration
15.5 Middle East Hepatic Encephalopathy Treatment Market Size and Forecast, By Distribution Channel
15.6 Middle East Hepatic Encephalopathy Treatment Market Size and Forecast, By Country
15.6.1. Saudi Arabia
15.6.2. UAE
15.6.3. Egypt
15.6.4. Kuwait
15.6.5. South Africa
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 Mallinckrodt Pharmaceuticals
17.1.1 Overview
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2. Salix Pharmaceuticals
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3. GlaxoSmithKline plc.
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Pfizer Inc.
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 ASKA Pharmaceutical Co., Ltd.
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 Bausch Health
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 Johnson & Johnson Services, Inc.
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Janssen Global Services
17..8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Takeda Pharmaceutical Company Limited
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 Merck & Co., Inc.
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies